VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need. VectivBio Holding AG is based in BASEL, Switzerland.
Revenue (Most Recent Fiscal Year) | $27.34M |
Net Income (Most Recent Fiscal Year) | $-93.74M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -- |
Return on Assets (Trailing 12 Months) | -- |
Current Ratio (Most Recent Fiscal Quarter) | -- |
Quick Ratio (Most Recent Fiscal Quarter) | -- |
Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $6.27 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | -- |
Free Float | -- |
Market Capitalization | -- |
Average Volume (Last 20 Days) | -- |
Beta (Past 60 Months) | -- |
Percentage Held By Insiders (Latest Annual Proxy Report) | 9.70% |
Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | -- |